Uppthera Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to serine/threonine-protein kinase PLK1 (STPK13) targeting moiety through a linker, acting as novel PLK1 protein degradation-inducing compounds with use for the treatment of cancer and neurological disorders.